VICL Vical Incorporated

+0.07  (+9%)
Previous Close 0.8
Open 0.8
Price To Book 0.48
Market Cap 19,871,912
Shares 22,841,278
Volume 1,660,658
Short Ratio
Av. Daily Volume 403,195

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 data released September 19, 2016 did not meet primary endpoint.
ASP0113 Vaccine
Kidney transplant recipients
Phase 2 trial did not meet primary endpoint - June 11, 2018.
VCL-HB01 HSV-2 Therapeutic Vaccine
Genital Herpes in Adults
Data did not meet primary endpoint
Vaxfectin-formulated therapeutic vaccine
Phase 3 data released January 22, 2018 - endpoints not met.
ASP0113 Vaccine
Hematopoietic cell transplant recipients
Phase 3 trial to be initiated 4Q 2019 with data due 4Q 2020.
Sofpironium Bromide
Axillary hyperhidrosis